RICHARD A. LARSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by anemia, neutropenia, or thrombocytopenia in various combinations (1, 2). The bone marrow is usually hypercellular or at least normocellular and may contain increased numbers of immature cells. The diagnosis rests on the finding of characteristic morphologic abnormalities in the peripheral blood as well as in the marrow. Among the commonest abnormalities are asynchrony of nuclear and cytoplasmic maturation, ringed sideroblasts, nuclear budding or premature karyorrhexis of erythrocyte nuclei, hypogranulated myeloid precursors, hyposegmented or hypersegmented nuclei in neutrophils, and micromegakaryocytes or megakaryocytes with a single large nucleus
LARSON RA. Management of Myelodysplastic Syndromes. Ann Intern Med. ;103:136–138. doi: 10.7326/0003-4819-103-1-136
Download citation file:
© 2019
Published: Ann Intern Med. 1985;103(1):136-138.
DOI: 10.7326/0003-4819-103-1-136
Results provided by: